Perry's The Chemotherapy Source Book

847 Pages·2012·26.63 MB·English

by  Doll, Donald C., Freter, Carl E., Perry, Michael Clinton

Perry’s
The Chemotherapy
Source Book
G
R
F I F T H E D I T I O N V
d
e
t
i
n
U r
i
.
s
-
EDITO&R s
9
n
Mic9hael C. Perry, MD, MS, MACP*
a
r
i
iProfessor Emeritus s
h
Nellie B. Smith Chair in Oncolorgy Emeritus
a
e
Division of Hematology/Medical Oncology
t
p
Department of Internal Medicine
.
University of Missouri
p
Ellis Fischel Cancer Center
i
v
Columbia, Missouri
*Deceased
ASSOCIATE EDITORS
Donald C. Doll, MD Carl E. Freter, MD, PhD, FACP
Professor Emeritus Professor of Clinical Medicine
Division of Hematology/Medical Oncology Nellie B. Smith Chair in Oncology
Department of Internal Medicine Director, Division of Hematology/Medical Oncology
University of Missouri Department of Internal Medicine
Ellis Fischel Cancer Center University of Missouri
Columbia, Missouri Ellis Fischel Cancer Center
Columbia, Missouri
tahir99 UnitedVRG
vip.persianss.ir
Senior Executive Editor: Jonathan W. Pine, Jr.
Senior Product Manager: Emilie Moyer
Vendor Manager: Alicia Jackson
Senior Manufacturing Coordinator: Benjamin Rivera
Director of Marketing: Caroline Foote
Designer: Teresa Mallon
Production Services: S4Carlisle
FIFTH Edition
© 2012 by LIPPINCOTT WILLIAMS & WILKINS, a WOLTERS KLUWER business
Two Commerce Square
2001 Market Street
Philadelphia, PA 19103, USA
LWW.com
Fourth Edition © 2008 by Lippincott Williams & Wilkins; Third Edition, © 2001 Lippincott Williams &
Wilkins; Second Edition, © 1996 Williams & Wilkins; First Edition, © 1992 Williams & Wilkins G
R
All rights reserved. This book is protected by copyright. No part of this book may be reproduced
in any form by any means, including photocopying, or utilized by any information storageV and
retrieval system without written permission from the copyright owner, except for brief quotations
d
embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as
part of their official duties as U.S. government employees are not covered by the abeove-mentioned
copyright. t
i
n
Printed in China
U r
i
.
Library of Congress Cataloging-in-Publication Data s
-
The chemotherapy source book. — 5th ed. / editors, Michael C. Perry, associate editors, Donald
& s
C. Doll, Carl E. Freter. 9
n
p. ; cm. 9
a
Includes bibliographical references and index.
r
ISBN 978-1-4511-0145-4 (alk. paper) i si
h
I. Perry, Michael C. (Michael Clinton), 1945- II. Doll, Donald C. III. Freter, Carl E.
r
[DNLM: 1. Neoplasms—drug theraapy. 2. Antineoplastic Agents—therapeutice use. QZ 267]
616.99’4061—dc23 t 2012001228
p
.
Care has been taken to confirm the accuracy of the inforpmation presented and to describe
generally accepted practices. However, the authors, editors, and publisher are not responsible for
i
errors or omissions or for any consequences from applicatvion of the information in this book and
make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of
the contents of the publication. Application of the information in a particular situation remains the
professional responsibility of the practitioner.
The authors, editors, and publisher have exerted every effort to ensure that drug selection
and dosage set forth in this text are in accordance with current recommendations and practice at
the time of publication. However, in view of ongoing research, changes in government regulations,
and the constant flow of information relating to drug therapy and drug reactions, the reader is urged
to check the package insert for each drug for any change in indications and dosage and for added
warnings and precautions. This is particularly important when the recommended agent is a new or
infrequently employed drug.
Some drugs and medical devices presented in the publication have Food and Drug
Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility
of the health care provider to ascertain the FDA status of each drug or device planned for use in their
clinical practice.
To purchase additional copies of this book, call our customer service department at [phone]
or fax orders to [phone]. International customers should call [phone].
Visit Lippincott Williams & Wilkins on the Internet: at LWW.com. Lippincott Williams & Wilkins
customer service representatives are available from 8:30 am to 6:00 pm, EST.
10 9 8 7 6 5 4 3 2 1
tahir99 UnitedVRG
vip.persianss.ir
Dedication and Memorial
This fifth edition of The Chemotherapy
Source Book is fondly dedicated to
Dr. Michael C. Perry. Through his
energy and vision The Chemotherapy
Source Book was born in 1992. To quote
Dr. Perry in his preface in the first edi-
tion, “The idea for this book arose from
my frustration at having to consult mul-
tiple sources for frequent, simple ques-
tions. I concluded that although there
were many excellent texts for medi-
cal oncologists, there was no one text
to satisfy my needs. I developed the
outline of the book over the next sev-
eral months, bouncing ideas off of col-
leagues whenever they came into range.
In preparing this book, I have been con-
cerned with the practicing oncologist.
I have imagined it as a well-worn text,
growing dog-eared with use, rather than
Michael C. Perry, MD
gathering dust on a shelf. With the pos-
1945-2011
sible exception of a reviewer, I doubt
anyone will intentionally sit down to
read it cover-to-cover. I anticipate that a reader may read a chapter here and there as his
or her interest dictates or use it to look up a specific point. I have resisted the temptation
to make a multi-authored book read as if it were written by a single individual, and I
would prefer that each chapter be thought of as a scholarly essay by the contributor(s).”
Sadly, Dr. Perry passed away before this edition of The Chemotherapy Source Book
could be completed. Dr. Donald Doll and Dr. Carl Freter have attempted the task
of compiling, editing, and finishing the current edition. As we do this, we know that
Dr. Perry is looking down on us smiling at our foibles and mistakes, which we are sure
he is just itching to correct.
Dr. Perry was many things to many people. He was a consummate physician, a
talented educator of great generosity, and a tireless researcher in translational science
and clinical trials to improve cancer care, and to impart the knowledge of how to
improve cancer care to his students after him. Dr. Perry was also the consummate gen-
tleman, friend, confidant, and raconteur whose presence among us we will forever miss.
Donald C. Doll, MD
Carl E. Freter, MD
tahir99 UnitedVRG
vip.persianss.ir
tahir99 UnitedVRG
vip.persianss.ir
Preface
Perry’s The Chemotherapy Source Book, now in its fifth edi- edition. Changes in management that have become evident
tion, was the first comprehensive book to piece together all since the previous edition are documented. The content has
current information on the chemotherapeutic management also been streamlined to provide essential information for
of cancer patients, and has now become a standard in many the busy practitioner.
circles. It provides information on the choice of chemother- In summary, Perry’s The Chemotherapy Source Book is
apeutic agents, the use of combination chemotherapy, and meant to serve as a “one-stop shop” for information on
the toxicity of individual drugs. Organized by site, this is the the choice of chemotherapeutic agents, treatment outlines,
only book of its kind to focus strictly on the clinical practice grading of side effects, and dose modification. It is our hope
of chemotherapy. There are other, smaller, texts (pocket that the fifth edition provides a practical reference for the
size) but none as complete. use of chemotherapy in oncology practice that is concise yet
This edition features updated drug information—over complete in its coverage of essential drug information for
20 new drugs have been added as well as new indications the busy clinician in private practice, hospital-based posi-
for existing ones. Moreover, the use and unique side effects tions, and academia alike.
of tyrosine kinase inhibitors, multitargeted agents, vascular
endothelial growth factor inhibitors, novel monoclonal anti- Donald C. Doll, MD
bodies, and immunotherapy have been incorporated in this Carl E. Freter, MD
Passages from the Preface are adapted from the proposal documents drafted by Michael C. Perry for this edition.
tahir99 UnitedVRvG
vip.persianss.ir
Preface to the First Edition
The idea for this book arose from my frustration at having modifications in renal and hepatic failure. It also has chap-
to consult multiple sources for frequent, simple questions. ters on gonadal toxicity and second malignancies, the most
I concluded that although there were many excellent texts recently recognized toxicities of successful chemotherapy.
for medical oncologists, there was no one text to satisfy my The vexing problem of chemotherapy in pregnancy is also
needs. I developed the outline for the book over the next addressed.
several months, bouncing ideas off of colleagues whenever The fourth section is a listing of combination chemo-
they came into range. therapy programs and the appropriate references. It is one
In preparing this book, I have been concerned with the man’s opinion (mine) of the most important historical and
practicing oncologist. I have imagined it as a well-worn current regimens likely to be in use. I realize that this listing
text, growing dog-eared with use, rather than gathering will not please everyone and that programs now in vogue
dust on a shelf. With the possible exception of a reviewer, may be replaced, hopefully by those offering higher com-
I doubt anyone will intentionally sit down to read it cover- plete response rates and improved survival.
to-cover. I anticipate that a reader may read a chapter here The fifth section, drug administration, is aimed at the
and there as his or her interest dictates or use it to look up pharmacist or nurse preparing chemotherapy, and the nurse
a specific point. I have resisted the temptation to make a who administers the therapy and interacts with the pharma-
multi-authored book read as if it were written by a single cist, patient, and physician.
individual, and I would prefer that each chapter be thought In Section Six, selected authorities address the therapy
of as a scholarly essay by the contributor(s). of specific tumors based on current knowledge. I anticipate
Section One deals in a practical way with the principles that this section will receive heavy use and may elicit differ-
of chemotherapy, that is, the rationale, scientific basis, and ing opinions.
various settings in which the drugs are currently used. The I am grateful to my administrative assistants, Beth Van
subsection on routes of administration explores the advan- Hove and Patty Moore, for their assistance and patience, to
tages and disadvantages of each route. As in other sections my wife Nancy and daughters Rebecca and Katherine for
of the book, I have been fortunate to attract authors who are allowing me to neglect them while I attempt to complete the
authorities in their areas. text, to my contributors for their enthusiasm and expertise,
Section Two, on chemotherapeutic drugs, discusses com- and to my teachers whom I have tried to emulate. A special
mercially available drugs by class, emphasizing their mecha- thanks also goes to the reference librarians, here and else-
nisms of action, pharmacology, toxicity, etc. in nine chapters. where, who helped with the elusive references, sources, and
There is also an extensive review on current investigational searches. The editors and staff at Williams & Wilkins have
agents to aid the oncologist, nurse, pharmacologist, etc. who been most helpful and supportive, especially Tim Satterfield,
may need information regarding these agents. This informa- Jonathan Pine, Carol Eckhart, and Charles Zeller. Their
tion is not readily available in one source elsewhere. advice and suggestions have made this a far better book than
Section Three includes 16 chapters by authorities on any effort of my own. I hope you enjoy our efforts.
the management of chemotherapeutic drug toxicity by
organ system and incorporates guidelines for dosage Michael C. Perry, MD
vi tahir99 UnitedVRG
vip.persianss.ir
Contributors
Taher Abu Hejleh, MBBS Anne Hudson Blaes, MD, MS
Hematology-Oncology Fellow Assistant Professor
Division of Hematology, Oncology and Blood & Marrow Department of Medicine
Transplantation, Department of Internal Medicine University of Minnesota
University of Iowa Hospitals and Clinics Minneapolis, Minnesota
Iowa City, Iowa
Ravi K. Bobba, MD
Susan K. Ailor, MD Fellow
Associate Professor Division of Hematology/Medical Oncology
Department of Dermatology University of Missouri
University of Missouri Columbia, Missouri
Columbia, Missouri
Rolando D. Breier, MD
Clay M. Anderson, MD, FACP Division of Hematology/Medical Oncology
Medical Director University of Missouri
NorthCare Hospice and Palliative Care Columbia, Missouri
Palliative Care
Michael T. Brennan, DDS, MHS
North Kansas City Hospital
Associate Chairman
North Kansas City, Missouri
Department of Oral Medicine
James O. Armitage, MD Carolinas Medical Center
The Joe Shapiro Professor of Medicine Charlotte, North Carolina
Department of Internal Medicine
Francis Buadi, MB ChB
University of Nebraska Medical Center
Assistant Professor
Omaha, Nebraska
Division of Hematology, Department of Medicine
Lynn S. Ashby, MD Mayo Clinic
NeuroOncology Program Rochester, Minnesota
Barrow Neurological Institute
Mohamad A. Cherry, MD
Phoenix, Arizona
Assistant Professor
Stacey H. Bain, PhD Department of Internal Medicine, Hematology Oncology Section
Vice President University of Oklahoma School of Medicine
Clinical Product Development Oklahoma City, Oklahoma
BioNumerik Pharmaceuticals, Inc.
Nicholas W. Choong, MD
San Antonio, Texas
Assistant Professor
Daniel J. Becker, MD Division of Hematology and Oncology
Division of Hematology/Oncology, Department of Internal Medical College of Wisconsin
Medicine Milwaukee, Wisconsin
St. Luke’s Roosevelt Hospital
Rashmi Chugh, MD
Assistant Clinical Professor of Medicine
Assistant Professor
Department of Internal Medicine
Department of Internal Medicine
Columbia University
University of Michigan Medical School
New York, New York
University of Michigan Hospitals
Philip J. Bierman, MD Ann Arbor, Michigan
Professor
Gerald H. Clamon, MD
Department of Internal Medicine
Professor
University of Nebraska Medical Center
Department of Internal Medicine
Omaha, Nebraska
University of Iowa School of Medicine
Susan Blackwell, MHS, PA-C Iowa City, Iowa
Senior Physician Assistant
Christopher R. Cogle, MD
Department of Medicine
Associate Professor
Division of Hematology and Oncology
Division of Hematology/Oncology, Department of Medicine
Duke University Medical Center
University of Florida
Durham, North Carolina
Gainesville, Florida
tahir99 UnitedvViRiG
vip.persianss.ir
viii Contributors
John T. Cole, MD Carl E. Freter, MD, PhD, FACP
Chairman, South Shore Clinics Professor of Clinical Medicine
Departmet of Hematology and Oncology Nellie B. Smith Chair in Oncology
Ochsner Health System Director, Division of Hematology/Medical Oncology
Hematology and Oncology Department of Internal Medicine
Louisiana State University Health Sciences Center University of Missouri
New Orleans, Louisiana Ellis Fischel Cancer Center
Columbia, Missouri
Jeffrey Crawford, MD
George Barth Geller Professor for Research in Cancer, Teresa A. Gilewski, MD
Chief of Division of Medical Oncology Associate Attending
Department of Medicine Department of Medicine
Duke University Medical Center Memorial Sloan-Kettering Cancer Center
Durham, North Carolina New York, New York
Paul S. Dale, MD James H. Goldie, MD, FRCPC
Chief Emeritus Clinical Professor of Medicine
Surgical Oncology BC Cancer Research Center
Professor University of British Columbia
Clinical Surgery Vancouver, British Columbia, Canda
University of Missouri
Keith Goldstein, MD
Columbia, Missouri
Oncology and Hematology Associates
Rajiv Dhand, MD, FCCP, FACP, FAARC Tamarac, Florida
Professor of Medicine
Ramaswamy Govindan, MD
Internal Medicine
Professor of Internal Medicine
University of Missouri
Department of Internal Medicine
Columbia, Missouri
Washington University School of Medicine
Donald C. Doll, MD St. Louis, Missouri
Professor Emeritus
Stephen L. Graziano, MD
Division of Hematology/Medical Oncology
Professor
Department of Internal Medicine
Department of Medicine
University of Missouri
State University of New York Upstate Medical University
Ellis Fischel Cancer Center
Syracuse, New York
Columbia, Missouri
F. Anthony Greco, MD
Steven M. Duffy, MD
Director
Fellow
Sarah Cannon Cancer Center
Division of Hematology and Oncology,
Sarah Cannon Research Institute
Department of Medicine
Nashville, Tennessee
Upstate Medical University
Syracuse, New York Morris D. Groves, MD, JD
Associate Professor
William D. Ensminger, MD, PhD
Department of Neuro-Oncology
Professor of Internal Medicine
The University of Texas MD Anderson Cancer Center
Professor of Pharmacology
Houston, Texas
University of Michigan
Ann Arbor, Michigan Barbara A. Gruner, MD
Assistant Professor
Justin D. Floyd, DO
Department of Child Health
Cancer Care Specialists of Central Illinois
University of Missouri
Crossroads Cancer Center
Columbia, Missouri
Effingham, Illinois
Assistant Professor of Clinical Medicine Vamsi P. Guntur, MD, MSc
Department of Internal Medicine Assistant Professor of Medicine
Washington University School of Medicine Division of Pulmonary, Critical Care and Environmental Medicine
St. Louis, Missouri Department of Internal Medicine
University of Missouri
Arthur D. Forman, MD
Columbia, Missouri
Associate Professor
Department of Neuro-Oncology Shadi Haddadin, MD
MD Anderson Cancer Center Division of Hematology/Medical Oncology
Houston, Texas University of Missouri
Columbia, Missouri
tahir99 UnitedVRG
vip.persianss.ir
Contributors ix
John D. Hainsworth, MD C. Daniel Kingsley, MD, FACP
Chief Scientific Officer Clinical Assistant Professor
Sarah Cannon Research Institute Department of Internal Medicine
Nashville, Tennessee University of Alabama at Birmingham, Huntsville
Clearview Cancer Institute
Monique A. Hartley, MD, MS
Huntsville, Alabama
Staff Physician
Department of Medicine Catherine E. Klein, MD
New York University Medical Center Professor of Medicine
New York, New York University of Colorado
Woodhull Medical Center Aurora, Colorado
Brooklyn, New York Chief, Hematology/Medical Oncology
Veterans Affairs Eastern Colorado Health Care System
Frederick H. Hausheer, MD, FACP
Denver, Colorado
Chairman & Chief Executive Officer
BioNumerik Pharmaceuticals, Inc. Mark Klein, MD
San Antonio, Texas Assistant Professor
Associate Professor University of Minnesota
Medical Oncology Veterans Affairs Medical Center
The Johns Hopkins Oncology Center Minneapolis, Minnesota
Baltimore, Maryland
Rami S. Komrokji, MD
Mark I. Hunter, MD Clinical Director
Assistant Professor of Medicine Department of Malignant Hematology
Obstetrics, Gynecology, and Women’s Health Moffitt Cancer Center & Research Institute
Director, Gynecologic Oncology Associate Professor
University of Missouri Department of Oncologic Sciences
Columbia, Missouri University of South Florida
Tampa, Florida
Maha H. Hussain, MD, FACP
Professor of Medicine and Urology Robert A. Kyle, MD
Department of Internal Medicine Professor of Medicine, Laboratory Medicine and Pathology
University of Michigan Hematology
Ann Arbor, Michigan Mayo Clinic College of Medicine
Rochester, Minnesota
Preetesh Jain, MD, DM
Research Scholar Rajesh V. Lalla, DDS, PhD, CCRP, DABOM
The Chronic Lymphocytic Leukemia Research and Treatment Assistant Professor
Program Section of Oral Medicine
Feinstein Institute For Medical Research University of Connecticut Health Center
North Shore Long Island-Jewish Health System Department of Dentistry
Manhasset, New York John Dempsey Hospital
Farmington, Connecticut
Carl G. Kardinal, MD, FACP
Margaret Proctor Mulligan Professor of Clinical Medicine Victor A. Levin, MD
Division of Hematology/Medical Oncology Emeritus Professor
Department of Internal Medicine Department of Neuro-Oncology
University of Missouri The University of Texas MD Anderson Cancer Center
Columbia, Missouri Houston, Texas
Department of Neurosurgery and Neurosciences
Ramesh Khanna, MD
Kaiser Permanente
Karl D. Nolph, MD, Chair in Nephrology
Redwood City, California
Division of Nephrology
Professor of Medicine Jeanette A. Linebaugh, MSN, OCN, CCRP
University of Missouri Research Manager
Columbia, Missouri Clinical Trials Office
University of Missouri
Radwan F. Khozouz, MD
Ellis Fischel Cancer Center
Fellow
Columbia, Missouri
Division of Hematology/Medical Oncology
University of Missouri Alan F. List, MD
Columbia, Missouri Executive Vice President and Physician-in-Chief
Senior Member, Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
tahir99 UnitedVRG
vip.persianss.ir
x Contributors
Gary R. MacVicar, MD Howard Ozer, MD, PhD
Assistant Professor Section Chief
Division of Hematology/Oncology, Department of Internal Medicine Section Hematology/Oncology
Medicine University of Illinois at Chicago
Northwestern University Feinberg School of Medicine Interim Director UIC Cancer Center
Northwestern Memorial Hospital UIC Cancer Center
Chicago, Illinois University of Illinois at Chicago
Chicago, Illinois
Maurie Markman, MD
Cancer Treatment Centers of America Christos Papageorgio, MD, PhD, FACP
Philadelpiha, Pennsylvania SSM Cancer Care
Society of Operating Guidelines Regional Research Alliance
Stephen C. Medlin, DO, FACP
Director
Associate Professor
St. Louis, Missouri
Myeloma Institute for Research and Therapy
University of Arkansas Medical Sciences Roy A. Patchell, MD
Little Rock, Arkansas Chairman
Department of Neurology
Stacia C. Miles, MD
Barrow Neurological Institute
Section Chairman
Phoenix, Arizona
Department of Dermatology
Austin Diagnostic Clinic Steven Z. Pavletic, MD
Austin, Texas Head, Graft-versus-Host and Autoimmunity Unit
Experimental Transplantation and Immunology Branch
Daniel Morgensztern, MD
National Cancer Institute
Assistant Professor
Bethesda, Maryland
Division of Medical Oncology, Department of Medicine
Yale University School of Medicine Michael C. Perry, MD, MS, MACP*
Firm Chief for Medical Oncology Professor Emeritus
Smilow Cancer Hospital Nellie B. Smith Chair in Oncology Emeritus
New Haven, Connecticut Division of Hematology/Medical Oncology
Department of Internal Medicine
Patrick G. Morris, MB BCh, MSc
University of Missouri
Special Fellow
Ellis Fischel Cancer Center
Breast Cancer Medicine Service
Columbia, Missouri
Memorial Sloan-Kettering Cancer Center
New York, New York Douglas E. Peterson, DMD, PhD
Professor of Oral Medicine
Alfred I. Neugut, MD, PhD
Department of Oral Health and Diagnostic Sciences
Professor
University of Connecticut School of Dental Medicine
Departments of Medicine and Epidemiology
Co-Chair, Program in Head & Neck Cancer and Oral Oncology
College of Physicians and Surgeons and Mailman School of Public
Neag Comprehensive Cancer Center
Health, Columbia University
University of Connecticut Health Center
Division of Medical Oncology
Farmington, Connecticut
New York Presbyterian Hospital
New York, New York Bruce A. Peterson, MD
Professor of Medicine
Michael B. Nicholl, MD
Department of Medicine
Assistant Professor
University of Minnesota Medical School
Department of Surgery
Minneapolis, Minnesota
Surgical Oncology
University of Missouri Kanti R. Rai, MD
Columbia, Missouri Chief
Division of Hematology-Oncology
Larry Norton, MD
Long Island Jewish Medical Center
Deputy Physician-in-Chief for Breast Cancer Programs
New Hyde Park, New York
Medicine
Professor of Medicine
Memorial Sloan-Kettering Cancer Center
Departments of Medicine
New York, New York
Albert Einstein College of Medicine
Sonia Okuyama, MD Bronx, New York
Assistant Professor
Division of Medical Oncology
University of Colorado School of Medicine
Denver Health Medical Center
Denver, Colorado
*Deceased
tahir99 UnitedVRG
vip.persianss.ir